# **Special Issue**

# Ischemic Stroke: Current and Emerging Treatment Strategies

## Message from the Guest Editors

Stroke remains one of the leading causes of death and disability worldwide, with no effective neuroprotective treatments available beyond specialized care in the stroke unit. Recanalization through thrombolysis and/or mechanical thrombectomy has been shown to improve clinical outcomes for approximately 30% of patients with acute ischemic stroke. However, only about 15% of stroke patients meet the criteria for these treatments and, among those who do achieve successful recanalization, approximately 70% continue to experience significant disabilities or die. This Special Issue aims to explore novel pharmacological therapies for ischemic stroke that target alternative pathophysiological mechanisms beyond reperfusion. Authors are invited to submit original research and review articles on preclinical and clinical findings that contribute to a better understanding of the pathophysiological mechanisms of stroke as potential therapeutic targets. The proposed topics include neuroprotective agents, stem cell therapies, immune and inflammatory modulation, and innovations in rehabilitation and neurorepair.

### **Guest Editors**

### Dr. Mikahela A. López-Morales

- Unidad Mixta de Investigación Cerebrovascular, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain
- 2. Departamento de Fisioterapia, Universidad de Valencia, 46010 Valencia, Spain

## Dr. Macarena Hernández-Jiménez

Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain

### Deadline for manuscript submissions

30 January 2026



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/247430

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

